HAOXI HEALTH TECHNOLOGY LTD
HAONASDAQTrading Snapshot
- Day Range
- $2.67 – $2.76
- 52-Week Range
- $2.61 – $4,352.00
- Volume
- $3.84B
- Avg Volume
- $2.68B
- Shares Outstanding
- 350,231
- Next Earnings
- Nov 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $33M
- Last Q Revenue
- $34M
- P/E Ratio
- -1.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-12.35
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −75.3%
Why Investors Own HAO
- ✓High-growth profile — revenue up +25.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
HAOXI HEALTH TECHNOLOGY LTD
HAO
StockOtter · stockotter.spaceAbout HAOXI HEALTH TECHNOLOGY LTD
Haoxi Health Technology Limited, operating with its subsidiaries in China, specializes in providing digital marketing services. The company's offerings encompass online short video marketing, which it delivers to advertisers through its network of media partners, alongside custom-designed marketing strategies. These tailored solutions involve the careful planning, creation, distribution, and optimization of online advertisements across various digital platforms, all aimed at helping advertisers attract new customers, drive conversions, and cultivate consumer loyalty. Advertisements are strategically placed on leading online short video and social media platforms, including popular services like Toutiao, Douyin, WeChat, and Sina Weibo. Haoxi primarily serves an advertiser base within the healthcare industry. The company was founded in 2018 and is headquartered in Beijing, China.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Haoxi Health Technology Limited Announces 1-For-20 Reverse Share Split
BEIJING, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (NASDAQ: HAO; "we" or the "Company"), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par v
Haoxi Health Technology Limited (NASDAQ:HAO) Short Interest Up 810.7% in July
Haoxi Health Technology Limited (NASDAQ: HAO - Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 544,897 shares, an incre
Haoxi Health Technology Limited Announces Strategic Cooperation Framework with NOVA MEDIA to Develop An AI Digital Marketing System
BEIJING, July 14, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), a Beijing-headquartered online marketing solutions provider specializing in one-stop digital marketing services for the
Univest Securities, LLC Announces Closing of $4 Million Registered Direct Offering for its Client Haoxi Health Technology Ltd (NASDAQ: HAO)
New York, July 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the clo
Haoxi Health Technology Ltd Announces $4 Million Registered Direct Offering
BEIJING, July 10, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Ltd (NASDAQ: HAO) (“Haoxi” or the “Company”), today announced that it has entered into a definitive agreement with certain investors for the purchase and